Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

BACKGROUND: Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of ibrutinib combined with companion drugs for advanced renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Do-Youn, Maqueda, Maria Alsina, Quinn, David I., O’Dwyer, Peter J., Chau, Ian, Kim, Sun Young, Duran, Ignacio, Castellano, Daniel, Berlin, Jordan, Mellado, Begona, Williamson, Stephen K., Lee, Keun-Wook, Marti, Francisca, Mathew, Paul, Saif, Muhammad Wasif, Wang, Ding, Chong, Elizabeth, Hilger-Rolfe, Jacqueline, Dean, James P., Arkenau, Hendrik-Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623721/
https://www.ncbi.nlm.nih.gov/pubmed/37919668
http://dx.doi.org/10.1186/s12885-023-11539-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623721/
https://www.ncbi.nlm.nih.gov/pubmed/37919668
http://dx.doi.org/10.1186/s12885-023-11539-1

Ejemplares similares